Market revenue in 2021 | USD 40.9 million |
Market revenue in 2030 | USD 85.0 million |
Growth rate | 8.5% (CAGR from 2021 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Clinical |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Preclinical, Clinical |
Key market players worldwide | Labcorp Holdings Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, Toxikon, Intertek Group PLC, Pace Analytical Services, Icon PLC, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule bioanalytical testing services market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 66.99% in 2021. Horizon Databook has segmented the Italy large molecule bioanalytical testing services market based on preclinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The Italian large molecule bioanalytical testing market is driven by growing number of clinical trials in the country. For instance, Italy conducted 23,097 clinical trials between 1999 and 2019, according to WHO’s ICTRP. This contributes for over 4% of total clinical trials conducted globally in the same period.
Furthermore, according to Eurostat, the healthcare expenditure of the country was 8.8% of its GDP in 2017. Growing healthcare expenditure in the country will impel growth of large molecule bioanalytical testing market as well. In addition, R&D tax credit aims to encourage investment in R&D activities.
In 2019, the Italian pharmaceutical companies spend over USD 2 billion on R&D. Hence, the growing pharmaceutical R&D expenditure in the country will also boost the market. Moreover, the high geriatric population will increase the need for advancements in healthcare, driving the market. For instance, according to OECD, 22.7% of the Italian population was aged 65 or above in 2018.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy large molecule bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Italy large molecule bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account